CCL17: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CCL17. The page also collects GeneMedi's different modalities and formats products for CCL17 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CCL17 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for T lymphocytes, but not monocytes or granulocytes. The product of this gene binds to chemokine receptors CCR4 and CCR8. This chemokine plays important roles in T cell development in thymus as well as in trafficking and activation of mature T cells. [provided by RefSeq, Sep 2014]
| Target ID | GM-SE0742 |
| Target Name | CCL17 |
| Gene ID | 6361,20295,117518,574180,403586,493832,100140488,100630824 |
| Gene Symbol and Synonyms | A-152E5.3,ABCD-2,CCL17,SCYA17,Scya17l,TARC |
| Uniprot Accession | Q92583,Q9ERE0,Q8HYP9,Q95N01,Q8I021 |
| Uniprot Entry Name | CCL17_HUMAN,CCL17_MACMU,Q9ERE0_RAT,CCL17_FELCA,CCL17_CANLF |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Cytokine Target |
| Disease | Breast Cancer, Overactive bladder |
| Gene Ensembl | ENSG00000102970 |
| Target Classification | N/A |
Pre-made anti-CCL17 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CCL17 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CCL17 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Antibody Name | Species | Format | Classified by tag | Detail |
| Anti-CCL17 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Cytokine antibody | Detail |
Recombinant multi-species CCL17/ A-152E5.3/ ABCD-2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CCL17 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
| Products Name | Species | Expression Platform | Detail |
| CCL17 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |
Cytokine Products for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces human, Cynomolgus/ Rhesus macaque, rat, mouse chemokine (C-C motif) ligand 17 (CCL17) His+Avi (Biotinylated) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
CCL17 is a powerful chemokine produced in the thymus and by antigen-presenting cells like dendritic cells, macrophages, and monocytes. CCL17 plays a complex role in cancer. It attracts T-regulatory cells allowing for some cancers to evade an immune response. However, in other cancers, such as melanoma, an increase in CCL17 is linked to an improved outcome. CCL17 has also been linked to allergic diseases.
| Target | Species | Antigen Product Name | Bioactivity validation of Antigen | Antibody Product Name | Bioactivity validation of Antibodies | Detail |
| CCL17 | Human, Cynomolgus/Rhesus macaque, rat, mouse | chemokine (C-C motif) ligand 17 (CCL17) protein | Affintiy&bioactivity validated by ELISA, cell culture validated | Anti-CCL17 monoclonal antibody | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). | Detail |
Click to check more Cytokine Products
Pre-made CCL17 viral vector in GM Promise-ORFTM
| Cat No. | Products name | NM ID | Species | Type | Detail |
| vGMLP004761 | human CCL17 Lentivirus particle | NM_002987 | Human | Lentivirus particle | Detail |
| pGMLP004761 | human CCL17 Lentivirus plasmid | NM_002987 | Human | Lentivirus plasmid | Detail |
| pGMLPm001036 | mouse Ccl17 Lentivirus plasmid | NM_011332 | Mouse | Lentivirus plasmid | Detail |
| vGMLPm001036 | mouse Ccl17 Lentivirus particle | NM_011332 | Mouse | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Facebook
LinkedIn
Twitter
